GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infinity Pharmaceuticals Inc (OTCPK:INFIQ) » Definitions » Shiller PE Ratio

Infinity Pharmaceuticals (Infinity Pharmaceuticals) Shiller PE Ratio : (As of Apr. 26, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Infinity Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Infinity Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Infinity Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infinity Pharmaceuticals Shiller PE Ratio Chart

Infinity Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Infinity Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Infinity Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Infinity Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Infinity Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infinity Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Infinity Pharmaceuticals's Shiller PE Ratio falls into.



Infinity Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Infinity Pharmaceuticals's E10 for the quarter that ended in Jun. 2023 is calculated as:

For example, Infinity Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=-0.11/128.7287*128.7287
=-0.110

Current CPI (Jun. 2023) = 128.7287.

Infinity Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201309 -0.710 98.790 -0.925
201312 -0.680 98.326 -0.890
201403 -0.870 99.695 -1.123
201406 -0.780 100.560 -0.998
201409 2.030 100.428 2.602
201412 -0.830 99.070 -1.078
201503 -1.910 99.621 -2.468
201506 -0.780 100.684 -0.997
201509 0.840 100.392 1.077
201512 -0.800 99.792 -1.032
201603 -0.820 100.470 -1.051
201606 1.050 101.688 1.329
201609 -0.390 101.861 -0.493
201612 -0.460 101.863 -0.581
201703 -0.210 102.862 -0.263
201706 -0.340 103.349 -0.423
201709 -0.140 104.136 -0.173
201712 -0.140 104.011 -0.173
201803 -0.180 105.290 -0.220
201806 -0.120 106.317 -0.145
201809 0.230 106.507 0.278
201812 -0.140 105.998 -0.170
201903 -0.240 107.251 -0.288
201906 -0.180 108.070 -0.214
201909 -0.200 108.329 -0.238
201912 -0.200 108.420 -0.237
202003 -0.190 108.902 -0.225
202006 -0.160 108.767 -0.189
202009 -0.160 109.815 -0.188
202012 -0.170 109.897 -0.199
202103 -0.150 111.754 -0.173
202106 -0.130 114.631 -0.146
202109 -0.120 115.734 -0.133
202112 -0.130 117.630 -0.142
202203 -0.140 121.301 -0.149
202206 -0.130 125.017 -0.134
202209 -0.120 125.227 -0.123
202212 -0.110 125.222 -0.113
202303 -0.120 127.348 -0.121
202306 -0.110 128.729 -0.110

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Infinity Pharmaceuticals  (OTCPK:INFIQ) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Infinity Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Infinity Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Infinity Pharmaceuticals (Infinity Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1100 Massachusetts Avenue, Floor 4, Cambridge, MA, USA, 02138
Infinity Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products and those under development include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer. Infinity has a strategic partnership with AbbVie to develop some of its oncology related treatments. The company operates in only one segment which is drug development.
Executives
Adelene Q Perkins director, officer: President & CEO C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Stephane Peluso officer: Chief Scientific Officer 1100 MASSACHUSETTS AVENUE, CAMBRIDGE MA 02138
Brian Schwartz director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Robert Jr. Ilaria officer: Chief Medical Officer 1100 MASSACHUSETTS AVENUE, 4TH FLOOR, CAMBRIDGE MA 02138
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Richard Gaynor director C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
Jeffery Kutok officer: Chief Scientific Officer 784 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Samuel Agresta officer: Chief Medical Officer 784 MEMORIAL DR., CAMBRIDGE MA 02139
David W Beier director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Lawrence E Bloch officer: EVP, CFO & CBO
Michael Kauffman director C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Michael C Venuti director

Infinity Pharmaceuticals (Infinity Pharmaceuticals) Headlines

From GuruFocus